134 related articles for article (PubMed ID: 19292886)
1. CD98hc (SLC3A2), a novel marker in renal cell cancer.
Prager GW; Poettler M; Schmidinger M; Mazal PR; Susani M; Zielinski CC; Haitel A
Eur J Clin Invest; 2009 Apr; 39(4):304-10. PubMed ID: 19292886
[TBL] [Abstract][Full Text] [Related]
2. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.
Waldert M; Haitel A; Marberger M; Katzenbeisser D; Ozsoy M; Stadler E; Remzi M
BJU Int; 2008 Nov; 102(10):1381-4. PubMed ID: 18782311
[TBL] [Abstract][Full Text] [Related]
3. Exposed proliferation antigen 210 (XPA-210) in renal cell carcinoma (RCC) and oncocytoma: clinical utility and biological implications.
Kruck S; Hennenlotter J; Vogel U; Schilling D; Gakis G; Hevler J; Kuehs U; Stenzl A; Schwentner C
BJU Int; 2012 Feb; 109(4):634-8. PubMed ID: 21711439
[TBL] [Abstract][Full Text] [Related]
4. Expression of vitamin D3 receptor in kidney tumors.
Liu W; Tretiakova M; Kong J; Turkyilmaz M; Li YC; Krausz T
Hum Pathol; 2006 Oct; 37(10):1268-78. PubMed ID: 16949927
[TBL] [Abstract][Full Text] [Related]
5. CD70: a new tumor specific biomarker for renal cell carcinoma.
Junker K; Hindermann W; von Eggeling F; Diegmann J; Haessler K; Schubert J
J Urol; 2005 Jun; 173(6):2150-3. PubMed ID: 15879877
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
[TBL] [Abstract][Full Text] [Related]
7. Renal cell carcinoma marker reliably discriminates central nervous system haemangioblastoma from brain metastases of renal cell carcinoma.
Ingold B; Wild PJ; Nocito A; Amin MB; Storz M; Heppner FL; Moch H
Histopathology; 2008 May; 52(6):674-81. PubMed ID: 18393979
[TBL] [Abstract][Full Text] [Related]
8. Renal tubulocystic carcinoma is closely related to papillary renal cell carcinoma: implications for pathologic classification.
Zhou M; Yang XJ; Lopez JI; Shah RB; Hes O; Shen SS; Li R; Yang Y; Lin F; Elson P; Sercia L; Magi-Galluzzi C; Tubbs R
Am J Surg Pathol; 2009 Dec; 33(12):1840-9. PubMed ID: 19898225
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA 15a, inversely correlated to PKCĪ±, is a potential marker to differentiate between benign and malignant renal tumors in biopsy and urine samples.
von Brandenstein M; Pandarakalam JJ; Kroon L; Loeser H; Herden J; Braun G; Wendland K; Dienes HP; Engelmann U; Fries JW
Am J Pathol; 2012 May; 180(5):1787-97. PubMed ID: 22429968
[TBL] [Abstract][Full Text] [Related]
10. Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response.
Balamurugan K; Luu VD; Kaufmann MR; Hofmann VS; Boysen G; Barth S; Bordoli MR; Stiehl DP; Moch H; Schraml P; Wenger RH; Camenisch G
Oncogene; 2009 Sep; 28(37):3274-85. PubMed ID: 19581925
[TBL] [Abstract][Full Text] [Related]
11. Papillary renal cell carcinoma with oncocytic cells and nonoverlapping low grade nuclei: expanding the morphologic spectrum with emphasis on clinicopathologic, immunohistochemical and molecular features.
Kunju LP; Wojno K; Wolf JS; Cheng L; Shah RB
Hum Pathol; 2008 Jan; 39(1):96-101. PubMed ID: 17949780
[TBL] [Abstract][Full Text] [Related]
12. S100A1: a powerful marker to differentiate chromophobe renal cell carcinoma from renal oncocytoma.
Li G; Barthelemy A; Feng G; Gentil-Perret A; Peoc'h M; Genin C; Tostain J
Histopathology; 2007 Apr; 50(5):642-7. PubMed ID: 17394501
[TBL] [Abstract][Full Text] [Related]
13. The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma.
Faragalla H; Youssef YM; Scorilas A; Khalil B; White NM; Mejia-Guerrero S; Khella H; Jewett MA; Evans A; Lichner Z; Bjarnason G; Sugar L; Attalah MI; Yousef GM
J Mol Diagn; 2012 Jul; 14(4):385-92. PubMed ID: 22580180
[TBL] [Abstract][Full Text] [Related]
14. Identification of nicotinamide N-methyltransferase as a novel tumor marker for renal clear cell carcinoma.
Sartini D; Muzzonigro G; Milanese G; Pierella F; Rossi V; Emanuelli M
J Urol; 2006 Nov; 176(5):2248-54. PubMed ID: 17070307
[TBL] [Abstract][Full Text] [Related]
15. Mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type II expression in renal cell neoplasms: a tissue microarray and quantitative RT-PCR study.
Yakirevich E; Morris DJ; Tavares R; Meitner PA; Lechpammer M; Noble L; de Rodriguez AF; Gomez-Sanchez CE; Wang LJ; Sabo E; Delellis RA; Resnick MB
Am J Surg Pathol; 2008 Jun; 32(6):874-83. PubMed ID: 18408592
[TBL] [Abstract][Full Text] [Related]
16. Expression of GLUT1 in primary renal tumors: morphologic and biologic implications.
Ozcan A; Shen SS; Zhai QJ; Truong LD
Am J Clin Pathol; 2007 Aug; 128(2):245-54. PubMed ID: 17638658
[TBL] [Abstract][Full Text] [Related]
17. Oncocytic papillary renal cell carcinoma with solid architecture: mimic of renal oncocytoma.
Mai KT; Kohler DM; Robertson SJ; Belanger EC; Marginean EC
Pathol Int; 2008 Mar; 58(3):164-8. PubMed ID: 18251779
[TBL] [Abstract][Full Text] [Related]
18. Characterization of HLA-G expression in renal cell carcinoma.
Li BL; Lin A; Zhang XJ; Zhang X; Zhang JG; Wang Q; Zhou WJ; Chen HX; Wang TJ; Yan WH
Tissue Antigens; 2009 Sep; 74(3):213-21. PubMed ID: 19531101
[TBL] [Abstract][Full Text] [Related]
19. The usefulness of immunohistochemical markers in the differential diagnosis of renal neoplasms.
Zhou M; Roma A; Magi-Galluzzi C
Clin Lab Med; 2005 Jun; 25(2):247-57. PubMed ID: 15848735
[TBL] [Abstract][Full Text] [Related]
20. The utility of Pax-2 as an immunohistochemical marker for renal cell carcinoma in cytopathology.
Gokden N; Kemp SA; Gokden M
Diagn Cytopathol; 2008 Jul; 36(7):473-7. PubMed ID: 18528893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
